Ircolon

Trimebutine maleate, the active ingredient in Ircolon, is a spasmolytic / gastrointestinal motility modulator presented as an oral formulation for oral use. It is employed to manage functional gastrointestinal disorders such as irritable bowel syndrome, functional dyspepsia and related abdominal pain in adult patients.

GNH USA supplies Ircolon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ircolon is a spasmolytic that acts on gastrointestinal motility disorders. - Irritable bowel syndrome: helps normalize bowel movements and reduces abdominal discomfort. - Functional dyspepsia: alleviates post‑prandial fullness and upper abdominal pain. - Abdominal pain associated with gastrointestinal dysmotility: reduces visceral hypersensitivity and eases pain episodes.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Abdominal discomfort: transient cramping or bloating. - Dry mouth: reduced salivation. - Headache: mild tension‑type headache. - Dizziness: occasional light‑headedness. - Constipation: reduced bowel frequency.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, breathing difficulty. - Cardiac arrhythmia: irregular heartbeat requiring medical attention. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Neutropenia: marked reduction in white blood cells. - Hypotension: significant drop in blood pressure.

Patients should be aware of specific safety considerations before using Ircolon. - Hypersensitivity: avoid if known allergy to trimebutine or excipients. - Hepatic impairment: use with caution; monitor liver function. - Renal impairment: dose adjustment may be required in severe renal disease. - Concomitant opioid use: monitor for additive effects on gastrointestinal motility. - Severe constipation: discontinue if bowel obstruction is suspected. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Trimebutine may interact with other medicines; awareness of interaction severity is important.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase trimebutine levels. - Other opioid receptor agonists/antagonists: risk of additive gastrointestinal effects. - MAO inhibitors: potential for exaggerated autonomic responses.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce absorption. - Antihistamines with anticholinergic activity: could enhance antispasmodic effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): monitor for gastrointestinal irritation. - Other pro‑kinetic agents: assess for overlapping therapeutic actions.